Expression of pRb, p53, p16 and cyclin D1 and their clinical implications in urothelial carcinoma

Journal of Korean Medical Science

Volumn 25, Issue 10, 2010, Pages 1449-1455

  Lee, Kyungji ^a   Jung, Eun Sun ^a   Choi, Young Jin ^a   Lee, Kyo Young ^a   Lee, Ahwon ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Cyclin D1; P16; P53; Prb; Urothelial carcinoma

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER STAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 78449297462     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2010.25.10.1449     Document Type: Article

References (23)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Jung KW, Won YJ, Park S, Kong H, Sung J, Shin H, Park E, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci 2009; 24: 995-1003.
3. Shin HR, Jung KW, Won YJ, Park JG. 2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals. Cancer Res Treat 2004; 36: 103-14.
4. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. The world health organization classification of tumors of the urinary system and male genital system. Lyon : IARC press 2004; 92-109.
5. Margulis V, Lotan Y, Montorsi F, Shariat SF. Predicting survival after radical cystectomy for bladder cancer. BJU Int 2008; 102: 15-22.
6. Williams SG, Stein J P. Molecular pathways in bladder cancer. Urol Res 2004; 32: 373-85.
7. Im S, Yoo C, Jung JH, Choi HJ, Yoo J, Kang SJ, Lee KY. Alteration of G1/S cell cycle regulatory proteins in carcinogenesis of cutaneous squamous cell carcinomas. Korean J Pathol 2009; 43: 542-9.
8. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG, Benedict WF. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998; 58: 1090-4.
9. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 2007; 25: 468-75.
10. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004; 22: 1014-24.
11. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007; 20: 445-59.
12. Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010; 183: 68-75.
13. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004; 22: 1007-13.
14. Loden M, Stighall M, Nielsen NH, Roos G, Emdin SO, Ostlund H, Landberg G. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorogenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002; 21: 4680-90.
15. Knowles MA. What we could do now: molecular pathology of bladder cancer. Mol Pathol 2001; 54: 215-21.
16. Hitchings AW, Kumar M, Jordan S, Nargund V, Martin J, Berney DM. Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. Br J Cancer 2004; 91: 552-7.
17. Cho SY, Kim YS, Hong SJ. Prognostic significance of p53, pRb, and p21 (waf1) in T1G3 bladder cancer. Korean J Urol 2002; 43: 678-82.
18. Richter J, Befa L, Wagner U, Schraml P, Gasser TC, Moch H, Mihatsch MJ, Sauter G. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998; 153: 1615-21.
19. Simon R, Burger H, Semjonow A, Hertle L, Terpe HJ, Bocker W. Patterns of chromosomal imbalances in muscle invasive bladder cancer. Int J Oncol 2000; 17: 1025-9.
20. Xu HJ, Cairns P, Hu SX, Knowles MA, Benedict W F. Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression. Int J Cancer 1993; 53: 781-4.
21. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999; 18: 1197-203.
22. Ebstein JI. The lower urinary tract and male genital system. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors, Pathologic Basis of Disease. 8th ed. Philadelphia : Elsevier 2010; 976-80.
23. Amin MB, Gómez JA, Young RH. Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases. Am J Surg Pathol 1997; 21: 1057-68.